Table.

Clinical suggestions for using SGLT2i during COVID-19 pandemic

1. Patients with diabetes with documented COVID-19 infection

a. Avoid the addition of SGLT2i for better glycemic control

b. Discontinue previously prescribed SGLT2 during this period before complete recovery from COVID-19 infection because glycemic control can be usually achieved by titration of other antidiabetic agents (such as insulin)

2. Patients with diabetes without documented infection but under quarantine or isolation

a. Avoid the addition of SGLT2i for better glycemic control

b. Discontinue or decrease previously prescribed SGLT2i dosage because glycemic control can be usually achieved by up-titration of other oral antidiabetic agents or insulin

3. Patients with diabetes without documented infection and not under quarantine or isolation

a. Avoid the addition of SGLT2i before COVID-19 vaccine is available unless the therapeutic benefit clearly outweighs the risk of cardiovascular mortality

b. Do not increase previously prescribed SGLT2i dosage because glycemic control can be usually achieved by up-titration of other oral antidiabetic agents or insulin

COVID-19 = coronavirus infection disease 2019; SGLT2i = sodium glucose cotransporter-2 inhibitor.